February 14, 2013
- Revenues rise by 11.4% (9.8% at constant exchange rates) to EUR 1,219m
- Adjusted operating margin (adjusted EBITDA margin) amounts to 19.4%
- Net income grows by 22.2% to EUR 66.5m
- Proposed dividend of EUR 0.65 per share
- Presence in the emerging markets most recently expanded through two acquisitions in India
Gerresheimer AG, one of the leading worldwide partners of the pharma and healthcare industry, has closed the 2012 financial year with significant growth in revenues and profits. "We achieved all our targets in 2012. We recorded another year of strong growth in our business activities with the pharmaceutical sector, which once again proved to be relatively immune to cyclical effects. We are investing heavily in expanding our production capacity for medical devices such as prefilled glass syringes, insulin pens and inhalers. We are also focusing on the fast-growing emerging markets, especially in
. In 2012 we succeeded in expanding our position in
in particular with the acquisition of two companies there," says Uwe Röhrhoff, CEO of Gerresheimer AG.
In the 2012 financial year (
December 1, 2011
November 30, 2012
), Gerresheimer recorded substantial growth in revenues of 11.4%. Revenues rose to
. At constant exchange rates, revenues increased by 9.8%. In particular Gerresheimer achieved strong growth in the pharma segment coupled with good revenue results in the cosmetic glass business and the life science research segment.
Gerresheimer increased its operating result (adjusted EBITDA) by 8.8% to
in the 2012 financial year. The adjusted EBITDA margin amounts to 19.4%, compared to the prior year's 19.9%. Net income rose by 22.2% to
. Earnings per share rose by 19.3% to
. Adjusted earnings per share increased by 4.9% to
in the 2012 financial year (up from
in 2011). The company is expanding its production capacity for so-called medical devices, i.e. products for drug delivery such as prefilled glass syringes, insulin pens and asthma inhalers, in
and elsewhere. The Company is also focusing on growth in the emerging markets. In
Gerresheimer acquired Neutral Glass, one of
leading manufacturers of pharmaceutical vials. This was followed in
by the acquisition of the Indian company Triveni, the regional market leader for plastic pharmaceutical packaging and closures. Gerresheimer intends to achieve both organic growth and growth through acquisitions in the future.